← Back to headlines
Gilead to Acquire Ouro Medicines in $2.18 Billion Deal to Expand Inflammation Pipeline
Gilead Sciences has announced its intention to acquire Ouro Medicines in a deal valued at $2.18 billion, aiming to expand its pipeline of treatments for inflammatory diseases.
27 Mar, 00:55 — 27 Mar, 00:55
Sources
Showing 1 of 1 sources
Related Stories
Trump Administration Announces Major Oil Deal to Replenish U.S. Strategic Reserve
24m ago
NATO Warns of Escalating Russian Gray Zone Attacks Across Europe
46m ago
Investors Eye Jobs Data and Major Earnings Reports for Market Direction
1h ago
North Korea Replaces Defense Minister in Military Shake-Up
2h ago